Chen Mingxia
Date:2026-3-27 16:00:13 Views:
Chen Mingxia is the Director of Traditional Chinese Medicine (TCM) at Beijing Scrianen Pharmaceutical Co., Ltd. She has long been dedicated to frontline research and technological innovation in the development of new TCM drugs, leading and undertaking multiple original research programs for innovative medicines. She has participated in several major national and municipal projects, including the National Major New Drug Creation Programs during the 11th and 12th Five-Year Plan periods, the Innovation Fund for Small and Medium-Sized Technology-Based Enterprises of the Ministry of Science and Technology, the “Ten Diseases, Ten Drugs” initiative of Beijing Municipal Science & Technology Commission, and the “G20 Program for Biopharmaceutical Industry Leapfrog Development”. She has obtained three clinical trial approvals for new TCM drugs, has held more than 20 granted invention patents, and has published over 20 academic papers, addressing a range of key technical challenges.
She has contributed to the development of “Cerebral Revitalizing Tablets”, the first domestically approved innovative drug based on active components for the treatment of vascular dementia to enter clinical trials in China. In tackling challenges in industrialization, she led her team to overcome critical technical barriers—such as low drug loading and poor stability—in the development of Shenyu Xiaoyin Ointment, paving the way for translating TCM innovations from laboratory research to large-scale production.
Alongside her technological achievements, she has fostered talent through the “Staff Innovation Studio”, mentoring a cohort of young professionals and senior engineers and building a strong pipeline for TCM research and development. Driven by scientific and technological innovation, she has contributed to addressing major national needs and safeguarding public health, playing an important role in advancing the inheritance, innovation, and development of traditional Chinese medicine.
